Skip to Main Content

How does TICER work?

TICER is based on a simple decision framework, comparing no biomarker testing to biomarker testing, as illustrated in Figure a. If testing is performed, the biomarker prevalence α determines the proportion of patients for which a specific therapy is added or spared. Each endpoint is a clinical state corresponding to the patient’s progression free survival, overall survival, as well as associated costs and HRQOL.

Figure b displays the Cost (top) and HRQOL profile (bottom) for a general scenario. We consider treatment time t for targeted therapy, t(Targeted), for standard therapy, t(Standard), post-treatment stable disease (from t to PFS), and disease progression (PFS to OS) for both treatment arms. For simplicity, we assume that costs of quality of life of stable and progressed disease are equivalent between treatment arms.


Figure b displays the Cost (top) and HRQOL profile (bottom) for a general scenario. We consider treatment time t for targeted therapy, t(Targeted), for standard therapy, t(Standard), post-treatment stable disease (from t to PFS), and disease progression (PFS to OS) for both treatment arms. For simplicity, we assume that costs of quality of life of stable and progressed disease are equivalent between treatment arms.

The ICER (incremental cost effectiveness ratio) is a commonly reported statistic summarizing the cost-effectiveness of a scenario, and is reported as:

LinkToApp

Please access the app here: TICER